Compare OneSpan Inc (OSPN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Sana Biotechnology Inc — how do they compare? OneSpan Inc trades at $18.22 (market cap $662.97M), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Sana Biotechnology Inc is the larger of the two by market cap, and OneSpan Inc pays a 2.89% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and Sana Biotechnology Inc for 23 Days on average.
| OSPN | SANA | |
|---|---|---|
Market Cap | $662.97M | $836.71M |
Volume | 616,882 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $18.42 | $5.92 |
52-Week Low | $10.15 | $2.68 |
Typical Hold Time | 18 Days | 23 Days |
Enterprise Value | $632.05M | $749.96M |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OSPN trades at $18.22, up 2.94% today, with a bullish technical signal from moving averages and recent earnings beats. The company shows strong profitability with a 27.76% net income margin and a reasonable P/E of 10.16. Analyst consensus is strongly positive with 10 buy ratings. Recent news highlights investor attention and a new product launch, DigipassONE, supporting growth prospects.
The outlook for OSPN is favorable given consistent earnings outperformance and solid fundamentals, though negative net cash flow and competitive pressures pose risks. Upside potential hinges on execution of its subscription revenue growth strategy and market adoption of new authentication solutions.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
